Drug Costs, Federal Funding, New Partnerships, and Supreme Court Hearings
In this week’s BioBlog we explore the ending of a major contract between Express Scripts and Anthem, the continued battle over drug costs, an Upcoming meeting between the Trump administration and drug companies, a new partnership between Walgreens and Prime, and a highly anticipated hearing in the Supreme Court.
Express Scripts has decided not to renew their contract with Anthem due to a lawsuit last year.
Drug costs in the United States are up to five times that of the same drugs in Europe; the research and development costs cannot explain why they are so much higher here.
On May 8th the Trump administration is slated to meet with government researchers and drug companies to discuss federal funding in the private sector.
Recently Prime and Walgreens agreed to a deal that will form a new company to combine their mail service and specialty pharmacies businesses, which should help with cost efficiencies and coordinating health care.
This week the Supreme Court is set to hear arguments in a highly anticipated case regarding the procedures of bringing lower cost biosimilar medications to market.